CPY3A4-Mediated Lopinavir Bioactivation and Its Inhibition by Ritonavir
Authors:
- Feng LiFLFeng Li
- Jie LuJLJie Lu
- Xiaochao MaXMXiaochao Ma
- 1 January 2012
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 40 (1) , 18-24
Abstract
The combination of lopinavir (LPV) and ritonavir (RTV) is one of the preferred regimens for the treatment of HIV infection with confirmed efficacy and relatively low toxicity. LPV alone suffers the poor bioavailability due to its rapid and extensive metabolism. RTV boosts the plasma concentration of LPV by suppressing its metabolism and thus increasing LPV efficacy. In the current study, we found that RTV also inhibits LPV bioactivation. LPV bioactivation was investigated in human liver microsomes and cDNA-expressed human cytochromes P450. Twelve GSH-trapped reactive metabolites of LPV were identified by using a metabolomic approach. Semicarbazide-trapped reactive metabolites of LPV were also detected. RTV effectively suppressed all pathways of LPV bioactivation via CYP3A4 inhibition. Our data together with previous reports suggest that LPV plus RTV is an ideal combination because RTV not only boosts LPV plasma concentration, but it decreases LPV bioactivation.Keywords
This publication has 31 references indexed in Scilit:
- Low Incidence of Severe Liver Events in HIV Patients With and Without Hepatitis C or B Coinfection Receiving Lopinavir/RitonavirHIV Research & Clinical Practice, 2006
- Serious, multi-organ hypersensitivity to lopinavir alone, involving cutaneous-mucous rash, and myeloid, liver, and kidney functionAIDS, 2006
- Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometryJournal of Mass Spectrometry, 2006
- Lopinavir/RitonavirDrugs, 2006
- Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavirAIDS, 2005
- Mechanism-Based Inactivation of CYP3A by HIV Protease InhibitorsThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversityThe Pharmacogenomics Journal, 2004
- Potent Inhibition of the Cytochrome P-450 3A-Mediated Human Liver Microsomal Metabolism of a Novel HIV Protease Inhibitor by Ritonavir: A Positive Drug-Drug InteractionDrug Metabolism and Disposition, 1999
- CYTOCHROME P-450 3A4: Regulation and Role in Drug MetabolismAnnual Review of Pharmacology and Toxicology, 1999
- Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.Journal of Clinical Investigation, 1992